Actively Recruiting
Evaluating a Digital Intervention for Alleviating Diabetes-specific Emotional Distress in Adults Living With T2DM
Led by Gaia AG · Updated on 2024-11-08
250
Participants Needed
1
Research Sites
78 weeks
Total Duration
On this page
Sponsors
G
Gaia AG
Lead Sponsor
U
University Hospital Schleswig-Holstein
Collaborating Sponsor
AI-Summary
What this Trial Is About
This randomized controlled trial (RCT) with 250 patients suffering from type 2 diabetes mellitus (T2DM) aims to investigate the effectiveness of the self-guided digital therapeutic covivio. Inclusion criteria are: male, female or non-binary; age ≥ 18 years; confirmed diagnosis of T2DM; elevated levels of diabetes-specific emotional distress (Problem Areas in Diabetes \[PAID\]-20 score ≥ 33); consent to participate; sufficient German language skills. Exclusion criteria are: a diagnosis of type 1 diabetes mellitus (T1DM); current use of continuous glucose monitoring (CGM) as part of one's diabetes treatment; changes or planned changes in medication within 4 weeks before the baseline visit or in the subsequent 6 months; a bariatric operation within 4 weeks before the baseline visit or such an operation planned in the subsequent 6 months; changes or planned changes in psychotherapeutic treatment within 4 weeks before the baseline visit or in the subsequent 6 months. In addition, participants will be excluded from the study if they did not wear the CGM sensor for at least 6 of 7 days at baseline (before randomization), providing a minimum of 96 hours of glucose values including at least 24 hours overnight. Patients will be randomized and allocated in a 1:1 ratio to either an intervention group, in which they will receive access to covivio in addition to treatment as usual (TAU, n = 125), or to a control group, in which they will receive only TAU (n = 125). Co-primary endpoints of this trial will be the between-groups difference in the PAID-20 total score in the intervention and control group at six months, adjusted for the PAID-20 baseline score as well as the glucose management indicator (estimated HbA1c) assessed using continuous glucose monitoring devices (for a period of 7 days) at six months, adjusted for the baseline score. Secondary endpoints will be diabetes self-management skills, body mass index (BMI), and quality of life.
CONDITIONS
Official Title
Evaluating a Digital Intervention for Alleviating Diabetes-specific Emotional Distress in Adults Living With T2DM
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male, female or non-binary
- Age 18 years or older
- Confirmed diagnosis of type 2 diabetes mellitus through medical documentation of specific ICD-10-GM codes
- Elevated diabetes-specific emotional distress with a PAID-20 score of 33 or higher
- Access to a smartphone compatible with continuous glucose monitoring devices
- Consent to participate in the study
- Sufficient knowledge of the German language
You will not qualify if you...
- Diagnosis of type 1 diabetes mellitus
- Use of continuous glucose monitoring as part of current diabetes treatment
- Changes or planned changes in medication within 4 weeks before baseline or in the following 6 months
- Bariatric surgery within 4 weeks before baseline or planned within the next 6 months
- Changes or planned changes in psychotherapeutic treatment within 4 weeks before baseline or in the following 6 months
- Problems with continuous glucose monitoring sensor use or insufficient CGM data quality at baseline (wearing sensor less than 6 out of 7 days, less than 96 hours of glucose data, or less than 24 hours overnight data)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
GAIA AG
Hamburg, Germany, 22085
Actively Recruiting
Research Team
G
Gitta A Jacob, PhD
CONTACT
K
Katharina M Rischer, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here